Loading...

SPRY ARS PHARMACEUTICALS INC Legal Disputes 8-K Filing

RS P

SPRY

ARS PHARMACEUTICALS INC

(SPRY)

2023 8-K

Show Summary

Show Summary

Financial Statements

Investor Meetings

Financial Results

Financial Update

Financial Results

Collaboration Agreement

Supply Agreement

Manufacturing Agreement

Financial Results Announcement

Corporate Presentation Upda...

Presentation Update

Financial Results Announcement

Financial Results Announcement

Financial Update

Financial Results Announcement

Presentation Update

Financial Results Announcement

Annual Meeting of Stockholders

Regulation FD Disclosure

Financial Results Announcement

FDA Briefing Documents for ...

Financial Results Announcement

Presentation Update

Termination Agreement with ...

Financial Update

External Links:

ARS Pharmaceuticals received a Complete Response Letter from the FDA regarding their New Drug Application for neffy, a nasal spray for allergic reactions, and plans to appeal the decision.

AI Assistant

ARS PHARMACEUTICALS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.